Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter and Retrospective Observational Study to Analyze the Efficacy and Safety of the Combination With Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to Data Sheet

NCT02394015 is registered in ClinicalTrials.gov with Grupo Español de Investigación en Cáncer de Ovario as lead sponsor.

NCT NCT02394015
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02394015 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter and Retrospective Observational Study to Analyze the Efficacy and Safety of the Combination With Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to Data Sheet
Lead sponsor
Grupo Español de Investigación en Cáncer de Ovario
Phase
Observational
Overall status
Completed
Start date
May 6, 2013
Completion date
December 31, 2017
Enrollment
90 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian epithelial cancer recurrent